Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
Recruiting
Phase 3
Interventional Study
Tachycardia Atrial
Atrial Fibrillation
Atrial Flutter With Rapid Ventricular Response
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 153 (estimated)
- Sponsor
- Wake Forest University Health Sciences · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age \> 18 years or older
* Able to provide informed consent
* Primary diagnosis AFF RVR greater than or equal to 120 bpm
* Diltiazem as rate control agent
* English speaking
Exclusion Criteria:
* Hemodynamically unstable patients (SBP \<90, MAP \<65)
* Impaired consciousness…
Contacts